Module 3: Treatment of Chronic Immune-Mediated Polyneuropathies

Primary Audience:

This activity is intended to meet the educational needs of neurologists, NPs, PA, Nurses and Infusion Specialists managing patients with CIDP and MMN.

This module will discuss the treatments of CIDP and MMN, and emerging new formulations.

Brett Morrison, M.D., Ph.D.

Associate Professor of Neurology
Division of Neuromuscular Medicine
Program Director of Neuromuscular Medicine Fellowship
Director of Inpatient Neurology Consult Service
Johns Hopkins School of Medicine
Baltimore, MD

Dr. Brett Morrison specializes in neuromuscular disorders in adults including amyotrophic lateral sclerosis, motor neuropathies, myasthenia gravis and muscle diseases including myopathy and muscular dystrophy.

Dr. Morrison’s research interests include investigations into the basic mechanisms of acute denervation and the development of treatments for chronic denervating diseases such amyotrophic lateral sclerosis or motor neuropathies. Current research focuses on treatments designed to reduce muscle loss and atrophy, and thus preserve function, following denervation.

Dr. Brett Morrison received his M.D. and Ph.D. from Mount Sinai Medical School in New York City. He completed his medical internship at the University of Maryland and residency in neurology at The Johns Hopkins Hospital.

Incorporate updated clinical trial data of current and emerging IVIG, SCIG, and other immune modulators to the management of CIDP and MMN.